Kyphoscoliotic Ehlers-Danlos syndrome (kEDS) is a rare genetic disorder combining congenital hypotonia, congenital/early onset and progressive kyphoscoliosis, and generalized joint hypermobility. Vascular fragility is another characteristic of the disease rarely described. We report a severe case of kEDS-PLOD1 with several vascular complications leading to difficulties in disease management.
BACKGROUND AND PURPOSE: Vascular Ehlers-Danlos syndrome is a rare inherited connective tissue disorder because of pathogenic variants in the COL3A1 gene. Arterial complications can affect all anatomic areas and about 25% involve supra-aortic trunks (SATs) but no systematic assessment of cervical artery lesions has been made. The primary objective was to determine an accurate prevalence of spontaneous SAT lesions in a large series of patients with vascular Ehlers-Danlos syndrome at diagnosis and during follow-up. Secondary objectives were to study their neurological consequences (transient ischemic attack or stroke) and the possible relationships with sex, genotype, ascertainment status. METHODS: A retrospective review of a monocentric cohort of patients with molecularly proven vascular Ehlers-Danlos syndrome followed in a tertiary referral center from 2000 to 2017. RESULTS: One hundred forty-four patients were analyzed, 56.9% (n=82) had SAT lesions: 64.6% females, 74.4% index-case patients. Most lesions were identified in early arterial assessment (48% at first work-up, mean age of 35.7±13.0 years). Cumulative incidence of a first identification of a SAT lesion was 41.7% at 40 years old. On the complete period of survey, 183 SAT lesions (with 132 dissections and 33 aneurysms) were identified, mainly in internal carotid arteries (56.3%) and vertebral arteries (28.9%), more rarely in patients with COL3A1 null mutations (P=0.008). Transient ischemic attack or stroke were reported in n=16 (19.5%) of the 82 patients with SAT lesions without relation with age, sex, treatment, or hypertension. CONCLUSIONS: Cervical artery lesions are frequent and mostly asymptomatic in patients with vascular Ehlers-Danlos syndrome. Local dissections and aneurysms are the most frequent type of lesions, but transient ischemic attack or stroke seem rare.
Carotid Artery, Internal, Dissection , Ehlers-Danlos Syndrome , Stroke , Vertebral Artery Dissection , Adult , Carotid Artery, Internal, Dissection/epidemiology , Carotid Artery, Internal, Dissection/etiology , Carotid Artery, Internal, Dissection/physiopathology , Carotid Artery, Internal, Dissection/therapy , Ehlers-Danlos Syndrome/complications , Ehlers-Danlos Syndrome/epidemiology , Ehlers-Danlos Syndrome/physiopathology , Ehlers-Danlos Syndrome/therapy , Female , Humans , Male , Middle Aged , Stroke/epidemiology , Stroke/etiology , Stroke/physiopathology , Stroke/therapy , Vertebral Artery Dissection/epidemiology , Vertebral Artery Dissection/etiology , Vertebral Artery Dissection/physiopathology , Vertebral Artery Dissection/therapy
The effect of renal artery angioplasty on blood pressure in patients with true resistant hypertension and atherosclerotic renal artery stenosis has not been fully investigated due to the exclusion of these patients from most trials. In this study, we assessed the benefits of renal angioplasty on daytime ambulatory blood pressure (dABP) in this subgroup of patients. Medical records of our hypertension department were retrospectively analyzed from 2000 to 2016. Seventy-two patients were identified with resistant hypertension (dABP >135 or 85 mm Hg despite at least 3 antihypertensive drugs, including a diuretic) and atherosclerotic renal artery stenosis treated by angioplasty. Atherosclerotic renal artery stenosis was unilateral in 57 patients and bilateral in 15 patients. The mean age of the patients was 67.8±11.2 years; dABP was 157±16/82±10 mm Hg despite 4.0±1.0 antihypertensive treatments; estimated glomerular filtration rate was 52 (41-63) mL/min. After renal angioplasty, dABPM decreased by 14.0±17.3/6.4±8.7 mm Hg (P<0.001 for both), and the number of antihypertensive treatments decreased to 3.6±1.4 (P=0.002) with no significant change in estimated glomerular filtration rate. A high baseline systolic dABP and a low body mass index were independent predictors of systolic dABP changes. The decrease in dABP was confirmed in a subgroup of patients at one and 3 years of follow-up (N=31 and N=18 respectively, P≤0.001 for systolic and diastolic blood pressure at both visits). In this retrospective uncontrolled single-center study, angioplasty in patients with atherosclerotic renal artery stenosis and with true resistant hypertension significantly decreased dABP, reducing the need for antihypertensive treatment with no change in estimated glomerular filtration rate.
Angioplasty, Balloon/methods , Blood Pressure Monitoring, Ambulatory/methods , Hypertension, Renal/diagnosis , Renal Artery Obstruction/surgery , Aged , Atherosclerosis/complications , Atherosclerosis/diagnosis , Cohort Studies , Databases, Factual , Female , Follow-Up Studies , France , Hospitals, University , Humans , Hypertension, Renal/etiology , Hypertension, Renal/surgery , Male , Middle Aged , Recurrence , Renal Artery Obstruction/diagnostic imaging , Renal Artery Obstruction/etiology , Retrospective Studies , Risk Assessment , Stents , Treatment Outcome , Ultrasonography, Doppler
BACKGROUND: Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic connective tissue disorder secondary to pathogenic variants within the COL3A1 gene, resulting in exceptional arterial and organ fragility and premature death. The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality. OBJECTIVES: The authors herein describe the outcomes of a large cohort of vEDS patients followed ≤17 years in a single national referral center. METHODS: All patients with molecularly confirmed vEDS were included in a retrospective cohort study. After an initial work-up, patients were treated or recommended for treatment with celiprolol (≤400 mg/day) in addition to usual care and scheduled for yearly follow-up. vEDS-related events and deaths were collected and recorded for each patient. RESULTS: Between 2000 and 2017, 144 patients (median age at diagnosis 34.5 years, 91 probands) were included in this study. After a median follow-up of 5.3 years, overall patient survival was high (71.6%; 95% confidence interval: 50% to 90%) and dependent on the type of COL3A1 variant, age at diagnosis, and medical treatment. At the end of the study period, almost all patients (90.3%) were treated with celiprolol alone or in combination. More than two-thirds of patients remained clinically silent, despite a large number (51%) with previous arterial events or arterial lesions at molecular diagnosis. Patients treated with celiprolol had a better survival than others (p = 0.0004). The observed reduction in mortality was dose-dependent: the best protection was observed at the dose of 400 mg/day versus <400 mg/day (p = 0.003). During the period surveyed, the authors observed a statistically significant difference in the ratio of hospitalizations for acute arterial events/hospitalizations for regular follow-up before and after 2011. CONCLUSIONS: In this long-term survey, vEDS patients exhibited a low annual occurrence of arterial complications and a high survival rate, on which the overall medical care seems to have a positive influence.
Celiprolol/therapeutic use , Ehlers-Danlos Syndrome/drug therapy , Monitoring, Physiologic/methods , Adult , Cohort Studies , Dose-Response Relationship, Drug , Drug Administration Schedule , Ehlers-Danlos Syndrome/diagnosis , Ehlers-Danlos Syndrome/mortality , Female , Follow-Up Studies , Humans , Long-Term Care/methods , Male , Retrospective Studies , Severity of Illness Index , Survival Rate , Time Factors , Treatment Outcome
We describe here the successful scheduled treatment of varicose veins by radiofrequency segmental thermal ablation in a 43-year-old patient with vascular Ehlers-Danlos syndrome. Her venous disease started at the age of 16 years, 1 year prior to her first major Ehlers-Danlos syndrome-related event which led to the diagnosis of her genetic condition. Surgical stripping was contra-indicated because of Ehlers-Danlos syndrome at the age of 18 years. More than 20 years later, her venous disease had become highly symptomatic despite daily compression and pain medication. Venous reassessment evidenced incompetent right and left great saphenous and left small saphenous veins, with increased diameters of both sapheno-femoral and sapheno-popliteal junctions. Radiofrequency endovenous ablation rather than surgery was considered because of its minimally invasive nature and because of standardized energy delivery.All intended-to-be-treated incompetent saphenous vein segments were occluded successfully, followed by an important improvement of clinical disease severity at day 30, persistent at 1 year post-treatment. Duplex ultrasound confirmed closure and fibrotic retraction of all treated venous segments at 1 year. This report shows that radiofrequency endovenous ablation may be a safe and effective therapy of varicose veins in patients with diagnosed vascular Ehlers-Danlos syndrome.
Ablation Techniques/methods , Ehlers-Danlos Syndrome/surgery , Endovascular Procedures/methods , Saphenous Vein/surgery , Varicose Veins/surgery , Adult , Female , Humans
Vascular Ehlers-Danlos syndrome (vEDS) is a rare and severe autosomal dominant disorder caused by variants at the COL3A1 gene. Clinical characteristics and course of disease of 215 molecularly proven patients (146 index cases and 69 relatives) were analysed. We found 126 distincts variants that were divided into five groups: (1) Glycine substitutions (n=71), (2) splice-site and in-frame insertions-deletions (n=36), (3) variants leading to haplo-insufficiency (n=7), (4) non-glycine missense variants within the triple helix (n=4 variants), and (5) non-glycine missense variants or in-frame insertions-deletions, in the N- or C-terminal part of the protein (n=8). Overall, our cohort confirmed the severity of the disease with a median age at first complication of 29 years (IQR 22-39), the most frequent being arterial (48%) and digestive (24%) ruptures. Groups 2 and 1 were significantly more severe than groups 3-5, with extreme median ages at first major complication of 23-47 years. Patients of groups 3-5 had a less typical phenotype and remarkably absence of digestive events. The distribution of glycine-replacing amino acids was strongly biased towards more destabilizing residues of the collagen assembly. Thus the natural course of vEDS and the clinical phenotype of patients are influenced by the type of COL3A1 variant. This study also confirms that patients with variants located in the C- and N-termini or leading to haplo-insufficiency have milder course of the disease and less prevalent diagnostic criteria. These findings may help refine diagnostic strategy, genetic counselling and clinical care.
Collagen Type III/genetics , Ehlers-Danlos Syndrome/genetics , Gene Deletion , Mutation, Missense , Phenotype , Adult , Ehlers-Danlos Syndrome/pathology , Female , Humans , Male , Middle Aged
Introducción y objetivos. El estudio ecográfico de la composición de la placa de ateroma utilizando la mediana de niveles de gris resume la ecogenicidad a un valor global. Se propone agregar una dimensión a ese enfoque fragmentando la lesión en capas y construyendo una curva de ecolucencia en función de la profundidad. Métodos. Se analizaron placas en carótida y femoral de pacientes asintomáticos por el método de la mediana y por el nuevo método en capas. Se analizó la reproducibilidad interobservador de ambos procedimientos. Se estudiaron 3 factores: edad, género y tabaco. Las curvas de ecogenicidad se compararon entre grupos con un ANOVA de 2 vías. Resultados. La ecogenicidad de las placas en carótida y femoral resultó similar por ambos métodos. Las curvas de ecogenicidad crecen en función de la profundidad (r = 0,96; p < 0,001). El método global no arrojó diferencias de ecogenicidad para ningún factor. En las placas femorales, el método por capas detectó mayor ecogenicidad con la edad (p < 0,001) y no detectó diferencias con el género. Los fumadores mostraron menor ecogenicidad superficial con respecto a los no fumadores (p < 0,01). En las carótidas, aumentó la ecogenicidad con la edad (p < 0,01) y el género masculino (p < 0,01). La ecogenicidad en fumadores aumentó hacia el interior con respecto a los no fumadores (p < 0,05). La reproducibilidad de ambos métodos resultó similar. Conclusiones. El análisis por capas resultó más efectivo que el método global para identificar la influencia de la edad, el género y el tabaco sobre la ecogenicidad de placas de ateroma (AU)
Introduction and objectives. Echographic studies of the composition of atheromatous plaques make use of the median gray level, which provides an overall measure of echogenicity. We propose adding an additional dimension to this approach by dividing the lesion into layers and generating a curve that shows the variation in echolucency with depth. Methods. Femoral and carotid plaques in asymptomatic patients was investigated using both the median gray level and new layer methods. Interobserver variability was assessed for both methods. Three risk factors were studied: age, gender, and smoking status. Differences in echogenicitydepth curves between different groups were assessed using 2-way ANOVA. Results. The 2 methods gave similar results for the mean echogenicity of carotid and femoral plaques. Echogenicity increased as a function of depth (r=0.96; P < .001). With the median gray level method, none of the risk factors produced a change in echogenicity. However, with the layer method, the echogenicity of femoral plaques was found to increase with age (P < .001), though gender had no effect. Moreover, the echogenicity of superficial layers was less in smokers than nonsmokers (P < .01). In carotid plaques, echogenicity increased with age (P < .01) and was higher in men (P < .01). The echogenicity of deep plaques was greater in smokers than nonsmokers (P < .05). The reproducibility of the 2 methods was similar. Conclusions. The layer method was more effective than the median gray level method for identifying the effect of age, sex and smoking status on the echogenicity of atheromatous plaques (AU)
Humans , Male , Middle Aged , Carotid Artery, External , Carotid Artery, Internal , Carotid Artery Thrombosis , Ultrasonography/methods , Risk Factors , Vascular Diseases , Analysis of Variance , Informed Consent/standards , Body Mass Index , Blood Pressure/radiation effects
INTRODUCTION AND OBJECTIVES: Echographic studies of the composition of atheromatous plaque make use of the median gray level, which provides an overall measure of echogenicity. We propose adding an additional dimension to this approach by dividing the lesion into layers and generating a curve that shows the variation in echolucency with depth. METHODS: Femoral and carotid plaque in asymptomatic patients was investigated using both the median gray level and new layer METHODS: Interobserver variability was assessed for both METHODS: Three risk factors were studied: age, gender and smoking status. Differences in echogenicity-depth curves between different groups were assessed using two-way ANOVA. RESULTS: The two methods gave similar results for the mean echogenicity of carotid and femoral plaque. Echogenicity increased as a function of depth (r=0.96; P< .001). With the median gray level method, none of the risk factors produced a change in echogenicity. However, with the layer method, the echogenicity of femoral plaque was found to increase with age (P< .001), though gender had no effect. Moreover, the echogenicity of superficial layers was less in smokers than nonsmokers (P< .01). In carotid plaque, echogenicity increased with age (P< .01) and was higher in men (P< .01). The echogenicity of deep plaque was greater in smokers than nonsmokers (P< .05). The reproducibility of the two methods was similar. CONCLUSIONS: The layer method was more effective than the median gray level method for identifying the effect of age, sex and smoking status on the echogenicity of atheromatous plaque.
Atherosclerosis/diagnostic imaging , Carotid Arteries/diagnostic imaging , Femoral Artery/diagnostic imaging , Female , Humans , Male , Middle Aged , Ultrasonography/methods
The vascular type of Ehlers-Danlos syndrome (EDS) is a rare genetic disease transmitted as an autosomal dominant trait. It is distinguished from other forms of EDS by its unstable acrogeric morphotype and by vascular, gastrointestinal, and obstetrical complications. Diagnosis is based on various clinical signs, noninvasive imaging, and on the identification of a mutation of the COL3A1 gene, which provides diagnostic certainty but has a sensitivity of only 61%. When two major diagnostic criteria are present, a genetic test should be proposed, performed and its result presented in a multidisciplinary group. The precautionary principle requires that preventive measures be implemented when the diagnosis is suspected. All artery puncture, surgery, and gastrointestinal and uterine endoscopy are contraindicated, permissible only in life-threatening emergencies. Straining against a closed glottis and all other situations or drugs likely to raise blood pressure must be avoided. Contraception must be discussed to avoid pregnancy during the diagnostic period. Arterial lesions suggestive of the disease include dissecting aneurysms of the internal carotid and iliac arteries and of the anterior visceral branches of the abdominal aorta, fusiform aneurysms of the splenic artery, and early onset nontraumatic direct carotid-cavernous fistulae. Early-onset varicose veins, spontaneous peritonitis or unusually important perineal lesions after giving birth should also attract the physician's attention. Psychological treatment and support of patients and their families is essential, to help them both to live with their disease and to deal with the information and screening issues. The prognosis of Ehlers-Danlos syndrome, vascular type, is grim but there is wide interindividual variability and life expectancy is best among patients receiving regular follow-up. Management by an experienced multidisciplinary team, implementation of drastic prevention measures and, depending on the results of the BBEST study, the possible prescription of beta-blockers should help to reduce the risk of complications and justify hope for a real improvement in prognosis in the near future.
Ehlers-Danlos Syndrome , Adult , Ascorbic Acid/therapeutic use , Celiprolol/therapeutic use , Child , Clinical Trials as Topic , Collagen Type III/genetics , Contraception , Ehlers-Danlos Syndrome/complications , Ehlers-Danlos Syndrome/diagnosis , Ehlers-Danlos Syndrome/diagnostic imaging , Ehlers-Danlos Syndrome/drug therapy , Ehlers-Danlos Syndrome/genetics , Ehlers-Danlos Syndrome/physiopathology , Ehlers-Danlos Syndrome/therapy , Female , Genetic Counseling , Humans , Male , Mutation , Phenotype , Pregnancy , Pregnancy Complications , Prognosis , Tomography, X-Ray Computed , Ultrasonography, Doppler , Vasodilator Agents/therapeutic use
BACKGROUND: Relations of mediators of inflammation and hemostasis with preclinical atherosclerosis have been poorly analyzed. The aim of this study was to test potential associations of these blood markers with indicators of cardiovascular risk and atherosclerotic burden in asymptomatic, nonsmoking, hypercholesterolemic men. METHODS: A total of 87 men underwent cardiovascular risk assessment by means of 10-year Framingham risk calculation (median 9%) and atherosclerotic burden evaluation by means of ultrasonographic measurement of common carotid intima-media thickness and assessment of atherosclerotic plaques at three arterial sites (three-site plaques). RESULTS: Of the markers C-reactive protein, tumor necrosis factor-alpha, interleukin-10, factor VIIc, fibrinogen, plasminogen activator inhibitor-activator, soluble intercellular adhesion molecule-1, soluble P-selectin (sP-selectin), and von Willebrand factor, only sP-selectin was positively and independently associated with high Framingham risk score (>9%) (71.7 +/- 3.6 ng/mL, n = 33 v 59.6 +/- 2.8, n = 54; mean +/- SEM; P < .05) and with three-site plaques (75.4 +/- 5.7 ng/mL, n = 14 v 62.0 +/- 2.5, n = 73; P < .05). After adjustment for all of the above markers and for cardiovascular risk factors, odd ratios of having high Framingham risk and three-site plaques were 3.38 (1.43 to 10.21) and 5.23 (1.74 to 23.52) respectively, per 1-standard deviation increase in sP-selectin. CONCLUSIONS: These results confirm that among several hemostasis and inflammation mediators, only sP-selectin blood level was associated with preclinical atherosclerosis. It might confer to sP-selectin measurement a clinical usefulness for detecting and managing high cardiovascular risk in primary prevention.
Atherosclerosis/blood , Atherosclerosis/etiology , Hemostasis/physiology , Hypercholesterolemia/blood , Inflammation/blood , P-Selectin/blood , Adult , Atherosclerosis/physiopathology , Biomarkers/blood , C-Reactive Protein/metabolism , Cross-Sectional Studies , Factor VIII/metabolism , Fibrinogen/metabolism , Humans , Hypercholesterolemia/physiopathology , Interleukin-10/blood , Male , Middle Aged , Plasminogen Activator Inhibitor 1/blood , Risk Assessment , Tumor Necrosis Factor-alpha/blood , Tunica Intima/diagnostic imaging , Tunica Intima/pathology , Ultrasonography , von Willebrand Factor/metabolism
OBJECTIVE: We aimed to analyze the influence of hypertension on early large artery remodeling. METHODS AND RESULTS: Carotid intima-media thickness (IMT) and diameter were measured ultrasonographically in 394 normotensive subjects and 327 untreated and 528 treated hypertensive patients. IMT and diameter were increased in hypertensive groups, treated or untreated, compared with the normotensive group (P<0.001). Positive association existed between diameter and IMT in the overall study population (P<0.001), and this association interacted with the category of clinical groups (P<0.01). The slope of the diameter-IMT relationship was different between normotensive, untreated hypertensive, and treated hypertensive groups (P<0.01), with higher value in the treated hypertensive group than in untreated hypertensive and normotensive groups (P<0.05, P<0.01). Adjustment for blood pressure, lipid-lowering therapy, or multiple covariates (age, sex, systolic and diastolic blood pressures, body mass index, lipid-lowering therapy, smoking, and previous cardiovascular disease) did not abolish the diameter-IMT slope difference between clinical groups (P<0.01). CONCLUSIONS: The sensitivity of carotid artery enlargement in response to increase in wall thickness was unchanged in untreated hypertension but altered by antihypertensive therapy compared with the normotensive condition.
Carotid Arteries/diagnostic imaging , Hypertension/diagnostic imaging , Tunica Intima/diagnostic imaging , Adaptation, Physiological , Arteriosclerosis/complications , Arteriosclerosis/diagnostic imaging , Arteriosclerosis/physiopathology , Carotid Arteries/physiopathology , Female , Humans , Hypertension/complications , Hypertension/drug therapy , Hypertension/physiopathology , Male , Middle Aged , Multivariate Analysis , Stress, Mechanical , Tensile Strength , Tunica Intima/physiopathology , Ultrasonography
Extended coronary artery calcifications (CAC) are predictive for cardiovascular complications but little is known about factors likely to influence CAC deposit. An analysis was undertaken to assess the cardiovascular risk factors that are capable of predicting CAC change over time. A retrospective analysis of CAC change was carried out in 55 asymptomatic men who underwent sequential electron beam computed tomographic measurement of CAC score a mean of 3.3 years apart. To ensure maximal accuracy in CAC change analysis, patients were included who had an initial CAC score of 10 or greater and with difference between both scores of 20% or greater of the initial score. The annual change rate in CAC score was calculated by dividing the change in CAC score by the interval between scores. Subjects' risk factors were analyzed and included body mass index, blood pressure, blood lipids and glucose, plasma lipoprotein(a) and fibrinogen, smoking status, and family history of coronary heart disease. The annual change rate in CAC score correlated positively with lipoprotein(a) (r = 0.42, p<0.01) and with initial CAC score (r = 0.46, p<0.001) and these associations persisted in multivariate analysis (p = 0.01, p = 0.001 respectively, R2 = 0.31). In contrast, no association existed between annual CAC change and baseline values and follow-up changes of other risk factors. The association of lipoprotein(a) with CAC progression in symptom-free patients with preexisting coronary calcifications provides new insights into the progression of coronary artery disease and may be useful for planning therapy and follow-up.
Calcinosis/epidemiology , Coronary Disease/epidemiology , Calcinosis/diagnostic imaging , Coronary Disease/diagnostic imaging , Disease Progression , Follow-Up Studies , Humans , Male , Middle Aged , Multivariate Analysis , Predictive Value of Tests , Retrospective Studies , Risk Factors , Time Factors , Tomography, X-Ray Computed
